Back to Search
Start Over
Impact of patient face mask use on endophthalmitis after intravitreal anti-VEGF injections
- Source :
- Canadian Journal of Ophthalmology. 57:364-369
- Publication Year :
- 2022
- Publisher :
- Elsevier BV, 2022.
-
Abstract
- Objective To compare the incidence of endophthalmitis after intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections with and without patient face masking. Design Two-centre retrospective cohort study Participants Patients receiving a total of 28 501 injections (period 1 before masking: n = 13 863; period 2 after masking: n = 14 638) Methods Periods before and after implementation of patient masking were compared: period 1 (July–December 2019) and period 2 (July–December 2020). All patients requiring treatment for endophthalmitis following intravitreal anti-VEGF injections were reviewed. Endophthalmitis risks were compared. Statistical simulations were run to determine the number of injections or endophthalmitis cases required to detect a statistically significant difference between both periods. Results Five patients (0.036%) had endophthalmitis in period 1 compared with 7 patients (0.048%) in period 2. Odds ratio, 95% confidence interval, for risk of patient masking was 1.326, 0.421–4.179 (p = 0.63). Three patients (0.022%) in period 1 had culture-positive endophthalmitis compared with 2 patients (0.014%) in period 2. Risk of patient masking for culture-positive endophthalmitis was 0.631, 0.105–3.779 (p = 0.61). Assuming similar rates of endophthalmitis, 476,806 injections in both groups would be required to detect a significant difference. Alternatively, assuming that masking would increase endophthalmitis risk in period 2, a significant difference would require twice as many cases (n = 15, 0.102%) for a risk of 2.843, 1.033–7.825 (p = 0.043). Conclusions The implementation of patient masking in clinical practice did not significantly alter the rate of endophthalmitis following intravitreal anti-VEGF injections.
- Subjects :
- Vascular Endothelial Growth Factor A
medicine.medical_specialty
Angiogenesis Inhibitors
Eye Infections, Bacterial
Endophthalmitis
Ranibizumab
Ophthalmology
Humans
Medicine
Retrospective Studies
Anti vegf
business.industry
Incidence
Incidence (epidemiology)
Significant difference
Masks
Retrospective cohort study
General Medicine
Odds ratio
medicine.disease
Confidence interval
Bevacizumab
Clinical Practice
Intravitreal Injections
business
Subjects
Details
- ISSN :
- 00084182
- Volume :
- 57
- Database :
- OpenAIRE
- Journal :
- Canadian Journal of Ophthalmology
- Accession number :
- edsair.doi.dedup.....a2f435aa6e21e80d441be579707c35bf
- Full Text :
- https://doi.org/10.1016/j.jcjo.2021.06.015